Skip to main content
letter
. 2017 Feb 21;129(18):2581–2584. doi: 10.1182/blood-2016-10-742437

Figure 1.

Figure 1. Ventricular tachycardia captured in patients on ibrutinib. (A) A brief run of nonsustained ventricular tachycardia is seen on telemetry shortly after a syncopal episode in a patient who had been taking ibrutinib 420 mg per day for 86 days. (B) A 20-beat run of polymorphic ventricular tachycardia experienced by the same patient with syncope while receiving ibrutinib. (C) Polymorphic ventricular tachycardia identified in a patient reporting presyncope after 28 days receiving ibrutinib 420 mg per day.

Ventricular tachycardia captured in patients on ibrutinib. (A) A brief run of nonsustained ventricular tachycardia is seen on telemetry shortly after a syncopal episode in a patient who had been taking ibrutinib 420 mg per day for 86 days. (B) A 20-beat run of polymorphic ventricular tachycardia experienced by the same patient with syncope while receiving ibrutinib. (C) Polymorphic ventricular tachycardia identified in a patient reporting presyncope after 28 days receiving ibrutinib 420 mg per day.